Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / BMNDF - Biomind finishes dosing in trial of inhalation therapy for treatment-resistant depression

BMNDF - Biomind finishes dosing in trial of inhalation therapy for treatment-resistant depression

Biomind Labs

  • Biomind Labs ( OTCQB:BMNDF ) said it completed dosing of 30 healthy people in a phase 2 trial of its drug BMND01 for treatment-resistant depression.
  • "The results of this first part of the world’s first clinical trial to test an inhaled formulation of DMT are expected to be ready in October 2022," said Biomind CEO Alejandro Antalich in a Sept. 21 press release.
  • The trial will evaluate the safety and and tolerability of BMND01, a N-dimethyltryptamine (DMT)-based inhaled formulation.

For further details see:

Biomind finishes dosing in trial of inhalation therapy for treatment-resistant depression
Stock Information
Company Name: Biomind Labs
Stock Symbol: BMNDF
Market: OTC
Website: biomindlabs.com
Menu
BMNDF BMNDF Quote BMNDF Short BMNDF News BMNDF Articles BMNDF Message Board
Get BMNDF Alerts

News, Short Squeeze, Breakout and More Instantly...